Here, we used a well-identified pMHC (NY-ESO-1157–165/HLA-A*02:01) as the cancer-specific antigen and selected a highly specific TCR clone with a very high affinity (1G4-113 clone, Kd at picomole level [12]) to target it. The gene discussed is HLA-A; the disease is cancer.